Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRPH 
ProPhase Labs Inc (PRPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PRPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.8
1 Year Target Price $13.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.37% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.01M USD | Price to earnings Ratio - | 1Y Target Price 13.8 |
Price to earnings Ratio - | 1Y Target Price 13.8 | ||
Volume (30-day avg) 1 | Beta -0.77 | 52 Weeks Range 0.22 - 2.72 | Updated Date 09/14/2025 |
52 Weeks Range 0.22 - 2.72 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -312.27% |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -171.81% |
Valuation
Trailing PE - | Forward PE 10.09 | Enterprise Value 25703112 | Price to Sales(TTM) 3.22 |
Enterprise Value 25703112 | Price to Sales(TTM) 3.22 | ||
Enterprise Value to Revenue 4.6 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 41541200 | Shares Floating 38222063 |
Shares Outstanding 41541200 | Shares Floating 38222063 | ||
Percent Insiders 7.99 | Percent Institutions 6.57 |
Upturn AI SWOT
ProPhase Labs Inc
Company Overview
History and Background
ProPhase Labs, Inc. (PRPH) was founded in 1976. Initially focused on the development and marketing of over-the-counter (OTC) healthcare products, it has expanded into diagnostic services and direct-to-consumer (DTC) genetic testing.
Core Business Areas
- Consumer Healthcare: Develops, manufactures, and markets OTC healthcare products, including dietary supplements and personal care items.
- Diagnostic Services: Provides PCR and other diagnostic testing services, focusing on respiratory viruses, COVID-19, and other infectious diseases.
- Genetics: Direct to Consumer Genetic DNA tests used for health and ancestry insights.
Leadership and Structure
Ted Karkus serves as the Chief Executive Officer and Chairman of the Board. The company has a typical corporate structure with various departments and executives overseeing different aspects of the business.
Top Products and Market Share
Key Offerings
- Cold-EEZE: OTC cold remedy lozenges and other products. Market share varies significantly and is subject to strong competition from major pharmaceutical companies like Procter & Gamble (Vicks) and Reckitt Benckiser (Strepsils). Revenue for Cold-EEZE can fluctuate based on cold and flu seasons.
- BE-ON-Demand: Bacterial DNA test kits and interpretation products. Market share is growing as this is a new product being introduced to the market. Key competitors include many popular genetic tests, such as AncestryDNA, 23andMe, MyHeritage DNA.
- Diagnostic Testing Services: COVID-19, Respiratory Virus, Flu and other PCR tests. Market share has significantly decreased since 2021. Competitors include Quest Diagnostics (DGX) and LabCorp (LH).
Market Dynamics
Industry Overview
The OTC healthcare market is mature and highly competitive. The diagnostic testing market is experiencing growth due to increased awareness of preventive healthcare. The Genetic DNA test market is a growing field.
Positioning
ProPhase Labs aims to leverage its existing OTC product portfolio and expand into diagnostic services to diversify revenue streams. It is positioned as a smaller player in a market dominated by larger, well-established companies.
Total Addressable Market (TAM)
The TAM for OTC drugs is estimated in the hundreds of billions of dollars globally. The TAM for diagnostic and genetic testing is also substantial and growing, estimated to be over $100 billion. ProPhase Labs' position is relatively small compared to the total available market.
Upturn SWOT Analysis
Strengths
- Established brand recognition with Cold-EEZE
- Diversification into diagnostic services
- Experienced management team
- Infrastructure for manufacturing and distribution
Weaknesses
- Small market share compared to major competitors
- Dependence on seasonal products
- Fluctuating revenue based on testing demand
- Limited financial resources
Opportunities
- Expanding diagnostic testing services
- Developing new OTC products
- Acquiring complementary businesses
- Entering new geographic markets
Threats
- Intense competition in the OTC market
- Changes in healthcare regulations
- Economic downturn affecting consumer spending
- New entrants in the diagnostic testing market
Competitors and Market Share
Key Competitors
- DGX
- LH
- PG
- DNA
Competitive Landscape
ProPhase Labs faces intense competition from larger companies with greater financial resources. Its advantage lies in its niche products and focused diagnostic offerings, but it needs to innovate and expand to maintain competitiveness.
Major Acquisitions
Neuronix
- Year: 2022
- Acquisition Price (USD millions): 1.05
- Strategic Rationale: Acquisition of Neuronix was used to create a new strategic division for the company. Neuronix has a patent pending medical device for helping in cognitive function.
Growth Trajectory and Initiatives
Historical Growth: Growth spiked in 2021 due to COVID-19 testing demand but has since declined.
Future Projections: Analyst estimates project modest growth in the OTC segment and continued expansion of diagnostic services, but the business will need to achieve economies of scale.
Recent Initiatives: Recent strategic initiatives include expanding the genetics division with direct-to-consumer testing and cost reduction strategies.
Summary
ProPhase Labs has evolved from an OTC healthcare company to one with diagnostic and genetics business units. The company experienced a significant revenue spike during the COVID-19 pandemic from testing services, but has struggled since then to maintain revenue due to increased competition in its core Cold-EEZE and diagnostic businesses. It needs to continue innovating in product and service offerings and improving operational efficiency. The company will need to watch out for external regulations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Company press releases
- Market research reports
Disclaimers:
This analysis is based on available information and does not constitute financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProPhase Labs Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 1997-01-16 | Chairman & CEO Mr. Ted William Karkus | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 96 | Website https://www.prophaselabs.com |
Full time employees 96 | Website https://www.prophaselabs.com | ||
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.